Growth hormone therapy in children with idiopathic short stature - the effect on appetite and appetite-regulating hormones: a pilot study

Endocr Res. 2019 Feb-May;44(1-2):16-26. doi: 10.1080/07435800.2018.1493598. Epub 2018 Jul 6.

Abstract

Aim: To investigate the effect of growth hormone (GH) therapy on appetite-regulating hormones and to examine the association between these hormones and the response to GH, body composition, and resting energy expenditure (REE).

Methods: Nine pre-pubertal children with idiopathic short stature underwent a standard meal test before and 4 months following initiation of GH treatment. Ghrelin, GLP-1, leptin, and insulin levels were measured; area under the curve (AUC) was calculated. Height, weight, body composition, REE, and insulin-like growth factor levels were recorded at baseline and after 4 and 12 months.

Results: Following 4 months of GH therapy, food intake increased, with increased height-standard deviation score (SDS), weight-SDS, and REE (p < .05). Significant changes in appetite-regulating hormones included a decrease in postprandial AUC ghrelin levels (p = .045) and fasting GLP-1 (p = .038), and an increase in fasting insulin (p = .043). Ghrelin levels before GH treatment were positively correlated with the changes in weight-SDS (fasting: r = .667, p = .05; AUC: r = .788, p = .012) and REE (fasting: r = .866, p = .005; AUC: r = .847, p = .008) following 4 months of GH therapy. Ghrelin AUC at 4 months was positively correlated with the changes in height-SDS (r = .741, p = .022) and fat-free-mass (r = .890, p = .001) at 12 months of GH treatment.

Conclusions: The reduction in ghrelin and GLP-1 following GH treatment suggests a role for GH in appetite regulation. Fasting and meal-AUC ghrelin levels may serve as biomarkers for predicting short-term (4 months) changes in weight and longer term (12 months) changes in height following GH treatment. The mechanisms linking GH with changes in appetite-regulating hormones remain to be elucidated.

Abbreviations: SDS: standard deviation score; REE: resting energy expenditure; SMT: standard meal test; AUC: area under the curve; ISS: idiopathic short stature; SGA: small for gestational age; FFM: fat-free-mass; FM: fat mass; EER: estimated energy requirements; DRI: dietary reference intakes; IQR: inter-quartile range.

Keywords: GLP-1; Ghrelin; Insulin; Leptin; standard meal test.

Publication types

  • Clinical Trial
  • Observational Study

MeSH terms

  • Appetite Regulation / drug effects*
  • Body Composition / drug effects
  • Body Height / drug effects*
  • Child
  • Dwarfism / drug therapy*
  • Energy Intake / drug effects
  • Energy Metabolism / drug effects
  • Female
  • Ghrelin / drug effects*
  • Glucagon-Like Peptide 1 / drug effects
  • Glucagon-Like Peptide 1 / metabolism*
  • Human Growth Hormone / administration & dosage
  • Human Growth Hormone / pharmacology*
  • Humans
  • Insulin / metabolism*
  • Leptin / metabolism*
  • Male
  • Pilot Projects
  • Prospective Studies
  • Treatment Outcome

Substances

  • Ghrelin
  • Insulin
  • Leptin
  • Human Growth Hormone
  • Glucagon-Like Peptide 1